These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

464 related articles for article (PubMed ID: 24728294)

  • 1. Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBEC-dependent mutations in breast cancer.
    Nik-Zainal S; Wedge DC; Alexandrov LB; Petljak M; Butler AP; Bolli N; Davies HR; Knappskog S; Martin S; Papaemmanuil E; Ramakrishna M; Shlien A; Simonic I; Xue Y; Tyler-Smith C; Campbell PJ; Stratton MR
    Nat Genet; 2014 May; 46(5):487-91. PubMed ID: 24728294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Germline APOBEC3B deletion is associated with breast cancer risk in an Asian multi-ethnic cohort and with immune cell presentation.
    Wen WX; Soo JS; Kwan PY; Hong E; Khang TF; Mariapun S; Lee CS; Hasan SN; Rajadurai P; Yip CH; Mohd Taib NA; Teo SH
    Breast Cancer Res; 2016 May; 18(1):56. PubMed ID: 27233495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrative genomic analyses of APOBEC-mutational signature, expression and germline deletion of APOBEC3 genes, and immunogenicity in multiple cancer types.
    Chen Z; Wen W; Bao J; Kuhs KL; Cai Q; Long J; Shu XO; Zheng W; Guo X
    BMC Med Genomics; 2019 Sep; 12(1):131. PubMed ID: 31533728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers.
    Chan K; Roberts SA; Klimczak LJ; Sterling JF; Saini N; Malc EP; Kim J; Kwiatkowski DJ; Fargo DC; Mieczkowski PA; Getz G; Gordenin DA
    Nat Genet; 2015 Sep; 47(9):1067-72. PubMed ID: 26258849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of functional germline variants and a deletion polymorphism in APOBEC3A and APOBEC3B on breast cancer risk and survival in a Swedish study population.
    Göhler S; Da Silva Filho MI; Johansson R; Enquist-Olsson K; Henriksson R; Hemminki K; Lenner P; Försti A
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):273-6. PubMed ID: 26320772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of gene expression and associated mutation profiles of APOBEC3A, APOBEC3B, REV1, UNG, and FHIT with chemosensitivity of cancer cell lines to drug treatment.
    Vural S; Simon R; Krushkal J
    Hum Genomics; 2018 Apr; 12(1):20. PubMed ID: 29642934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The 29.5 kb APOBEC3B Deletion Polymorphism Is Not Associated with Clinical Outcome of Breast Cancer.
    Liu J; Sieuwerts AM; Look MP; van der Vlugt-Daane M; Meijer-van Gelder ME; Foekens JA; Hollestelle A; Martens JW
    PLoS One; 2016; 11(8):e0161731. PubMed ID: 27552096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of germline variants in the APOBEC3 region with cancer risk and enrichment with APOBEC-signature mutations in tumors.
    Middlebrooks CD; Banday AR; Matsuda K; Udquim KI; Onabajo OO; Paquin A; Figueroa JD; Zhu B; Koutros S; Kubo M; Shuin T; Freedman ND; Kogevinas M; Malats N; Chanock SJ; Garcia-Closas M; Silverman DT; Rothman N; Prokunina-Olsson L
    Nat Genet; 2016 Nov; 48(11):1330-1338. PubMed ID: 27643540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of APOBEC3A/3B germline deletion polymorphism in breast, cervical and oral cancers from South India and its impact on miRNA regulation.
    Revathidevi S; Manikandan M; Rao AK; Vinothkumar V; Arunkumar G; Rajkumar KS; Ramani R; Rajaraman R; Ajay C; Munirajan AK
    Tumour Biol; 2016 Sep; 37(9):11983-11990. PubMed ID: 27155849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA deaminases induce break-associated mutation showers with implication of APOBEC3B and 3A in breast cancer kataegis.
    Taylor BJ; Nik-Zainal S; Wu YL; Stebbings LA; Raine K; Campbell PJ; Rada C; Stratton MR; Neuberger MS
    Elife; 2013 Apr; 2():e00534. PubMed ID: 23599896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Germline APOBEC3B deletion influences clinicopathological parameters in luminal-A breast cancer: evidences from a southern Brazilian cohort.
    Vitiello GAF; de Sousa Pereira N; Amarante MK; Banin-Hirata BK; Campos CZ; de Oliveira KB; Losi-Guembarovski R; Watanabe MAE
    J Cancer Res Clin Oncol; 2020 Jun; 146(6):1523-1532. PubMed ID: 32285256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. APOBEC3A is an oral cancer prognostic biomarker in Taiwanese carriers of an APOBEC deletion polymorphism.
    Chen TW; Lee CC; Liu H; Wu CS; Pickering CR; Huang PJ; Wang J; Chang IY; Yeh YM; Chen CD; Li HP; Luo JD; Tan BC; Chan TEH; Hsueh C; Chu LJ; Chen YT; Zhang B; Yang CY; Wu CC; Hsu CW; See LC; Tang P; Yu JS; Liao WC; Chiang WF; Rodriguez H; Myers JN; Chang KP; Chang YS
    Nat Commun; 2017 Sep; 8(1):465. PubMed ID: 28878238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. APOBEC3A is a prominent cytidine deaminase in breast cancer.
    Cortez LM; Brown AL; Dennis MA; Collins CD; Brown AJ; Mitchell D; Mertz TM; Roberts SA
    PLoS Genet; 2019 Dec; 15(12):e1008545. PubMed ID: 31841499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. APOBEC3A/B deletion polymorphism and cancer risk.
    Gansmo LB; Romundstad P; Hveem K; Vatten L; Nik-Zainal S; Lønning PE; Knappskog S
    Carcinogenesis; 2018 Feb; 39(2):118-124. PubMed ID: 29140415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrative genomic analysis reveals functional diversification of APOBEC gene family in breast cancer.
    Zhang Y; Delahanty R; Guo X; Zheng W; Long J
    Hum Genomics; 2015 Dec; 9():34. PubMed ID: 26682542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of the APOBEC3A/B deletion polymorphism on risk of ovarian cancer.
    Gansmo LB; Sofiyeva N; Bjørnslett M; Romundstad P; Hveem K; Vatten L; Dørum A; Lønning PE; Knappskog S
    Sci Rep; 2021 Dec; 11(1):23463. PubMed ID: 34873230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. APOBEC mediated mutagenesis drives genomic heterogeneity in endometriosis.
    Revathidevi S; Nakaoka H; Suda K; Fujito N; Munirajan AK; Yoshihara K; Enomoto T; Inoue I
    J Hum Genet; 2022 Jun; 67(6):323-329. PubMed ID: 35017684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FHIT loss-induced DNA damage creates optimal APOBEC substrates: Insights into APOBEC-mediated mutagenesis.
    Waters CE; Saldivar JC; Amin ZA; Schrock MS; Huebner K
    Oncotarget; 2015 Feb; 6(5):3409-19. PubMed ID: 25401976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic inhibitors of APOBEC3B-induced mutagenesis.
    Mertz TM; Rice-Reynolds E; Nguyen L; Wood A; Cordero C; Bray N; Harcy V; Vyas RK; Mitchell D; Lobachev K; Roberts SA
    Genome Res; 2023 Sep; 33(9):1568-1581. PubMed ID: 37532520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical implications of APOBEC3A and 3B expression in patients with breast cancer.
    Kim YS; Sun S; Yoon JS; Ko YH; Won HS; Kim JS
    PLoS One; 2020; 15(3):e0230261. PubMed ID: 32176735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.